A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 3 fixed doses of EAA-090 [perzinfotel] in adult outpatients with neuropathic pain associated with diabetic neuropathy

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 3 fixed doses of EAA-090 [perzinfotel] in adult outpatients with neuropathic pain associated with diabetic neuropathy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2013

At a glance

  • Drugs Perzinfotel (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top